Condition: Prostate Cancer Patients · Sponsor: Shanghai Jiao Tong University School of Medicine
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
This description comes directly from the study's public registry record.
Yu Sun, Ph.D · 86-21-54923302 · sunyu@sibs.ac.cn
Weijun Ma, Ph.D · 86-21-54923268 · wjma@sibs.ac.cn
Always discuss trial participation with your own doctor first.
| Qilu Hospital of Shandong University | Qingdao, Shandong, China | Recruiting |
| Zhongshan Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03258320